926276-19-9 Usage
Uses
Used in Pharmaceutical Industry:
(1S,3aR,6aS)-2-[(2S)-2-[[(2S)-2-Cyclohexyl-2-[(2-pyrazinylcarbonyl)amino]acetyl]amino]-3,3-dimethyl-1-oxobutyl]octahydrocyclopenta[c]pyrrole-1-carboxylic acid tert-butyl ester is used as an intermediate in the preparation of Telaprevir (T015650), a drug useful in the treatment of hepatitis C. Its unique structure and functional groups make it a valuable component in the synthesis of this therapeutic agent.
Used in COVID-19 Research:
(1S,3aR,6aS)-2-[(2S)-2-[[(2S)-2-Cyclohexyl-2-[(2-pyrazinylcarbonyl)amino]acetyl]amino]-3,3-dimethyl-1-oxobutyl]octahydrocyclopenta[c]pyrrole-1-carboxylic acid tert-butyl ester is also a COVID-19-related research product. Its potential applications in the development of treatments or vaccines for COVID-19 are currently being explored, highlighting its importance in ongoing scientific research.
Check Digit Verification of cas no
The CAS Registry Mumber 926276-19-9 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 9,2,6,2,7 and 6 respectively; the second part has 2 digits, 1 and 9 respectively.
Calculate Digit Verification of CAS Registry Number 926276-19:
(8*9)+(7*2)+(6*6)+(5*2)+(4*7)+(3*6)+(2*1)+(1*9)=189
189 % 10 = 9
So 926276-19-9 is a valid CAS Registry Number.
926276-19-9Relevant academic research and scientific papers
PROCESS FOR THE SYNTHESIS OF TELAPREVIR, OR PHARMACEUTICALLY ACCEPTABLE SALTS OR SOLVATES AS WELL AS INTERMEDIATE PRODUCTS THEREOF
-
Page/Page column 19-20, (2013/09/26)
The invention relates to a process for the preparation of telaprevir, or a pharmaceutically acceptable salt or solvate thereof, wherein the process requires a smaller number of process steps and/or does not require the use of toxic and instable compounds compared to the known processes. Another embodiment refers to telaprevir, or a pharmaceutically acceptable salt or solvate thereof as well as to intermediate products for preparation of the same, wherein the afore-mentioned products are obtained by the process described herein.
Processes and intermediates
-
Page/Page column 21; 47-48, (2010/11/26)
The invention relates to compounds and processes useful for the preparation of protease inhibitors, particularly serine protease inhibitors. The protease inhibitors are useful for treatment of HCV infections.
